Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 49 - Preparations for testing in vivo
Patents for A61K 49 - Preparations for testing in vivo (35,376)
10/2003
10/09/2003US20030190284 Agglomerated particles for aerosol drug delivery
10/09/2003US20030189182 Hyperpolarized gas containers, solenoids, transport and storage devices and associated transport and storage methods
10/09/2003CA2480664A1 Cancer associated protein phosphatases and their uses
10/09/2003CA2480631A1 Processes for manufacturing polymeric microspheres
10/09/2003CA2480209A1 Paramagnetic particles that provide improved relaxivity
10/09/2003CA2479750A1 Fibrinogen binding moieties
10/08/2003EP1350798A1 Allergenic protein HEV b III of natural rubber latex, its production and use in assays
10/08/2003EP1350797A1 Allergenic protein Hev b II of natural rubber latex, its production and use in assays
10/08/2003EP1350524A1 A MRI contrast medium composition
10/08/2003EP1350085A2 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
10/08/2003EP1349962A1 Methods and compositions for detecting polynucleotide duplex damage
10/08/2003EP1349939A2 Aminoacyl trna synthetases
10/08/2003EP1349920A2 Adenylate cyclases
10/08/2003EP1349490A2 Fluorescence-mediated molecular tomography
10/08/2003EP1141548B1 Peristaltic compressors adapted to non-relaxing compression of polarised gas
10/08/2003EP0533845B1 USING 5,10,15,20-TETRAKIS(r-CARBOXYPHENYL)PORPHINE FOR DETECTING AND TREATING LUNG CANCER
10/08/2003CN2577838Y Capillary ending embolism agent
10/07/2003US6631283 B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
10/07/2003US6630318 Prognostic evaluation of cancer
10/07/2003US6630127 Diagnosis of central nervous system disorders
10/07/2003US6630126 Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products
10/07/2003CA2223418C Polyoxyhydrocarbyl related products and methods for fluorescence assays
10/02/2003WO2003081612A1 Process for the preparation of nanosozed iron oxide by biomimetic route
10/02/2003WO2003080554A2 Iodinated triglyceride analogs
10/02/2003WO2003080544A1 Radiofluorination methods
10/02/2003WO2003080124A1 Monitoring marker
10/02/2003WO2003079966A2 Photo-active backbone cyclized somatostatin analogs for photodynamic therapy and imaging
10/02/2003WO2003079921A1 Diagnosis marker
10/02/2003WO2003010199A3 Identification of specific tumour antigens by means of the selection of cdna libraries with sera and the use of said antigens in diagnostic imaging techniques
10/02/2003US20030187247 Immunoglobulin for use in prevention and treatment of viral diseases; immunotheray; immunoassay
10/02/2003US20030186968 Psychological disorders; central nervous system disorders
10/02/2003US20030186869 Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
10/02/2003US20030186845 Compositions for preventing urinary calculus
10/02/2003US20030185896 Polymer particles include pores such that the predominant size of pores near the center of the particles is greater than the predominant size of pores adjacent to periphery of the particle
10/02/2003US20030185895 Spherical polymer particle (e.g., a polyvinyl acetal) having an internal reservoir region including large pores containing therapeutic agent and a metering region having fewer relatively large pores.
10/02/2003US20030185869 Having lysozyme adsorbed onto or associated with the surface of an active agent
10/02/2003US20030185832 Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker.
10/02/2003US20030185793 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
10/02/2003US20030185760 Paramagnetic particles that provide improved relaxivity
10/02/2003US20030185759 Aqueous solution and phosphatidyl serine stabilized microbubbles containing halogenated hydrocarbon gas, especially freon, C2F6, C3F8 or C4F10.
10/02/2003US20030185757 Iron-containing core, a primary coat (synthesis polymer) which is responsible for optimal sized nanoparticles, and a secondary coat (targeting polymer)
10/02/2003US20030185756 Carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues
10/02/2003US20030183962 Forming beads of a predetermined size from a starting material which is a template polymer or ice; contacting the beads with a structural polymer; crosslinking the structural polymer
10/02/2003CA2448807A1 Monitoring marker
10/02/2003CA2448805A1 Diagnosis marker
10/01/2003EP1348768A2 Method of treatment, diagnosis or detection of diabetes
10/01/2003EP1348026A2 Fibrin binding moieties useful as imaging agents
10/01/2003EP1347731A2 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
10/01/2003EP1094843B1 Targeted site specific drug delivery compositions and uses
10/01/2003CN1446229A Somatostatin analogues
10/01/2003CN1444997A Gastrointestinal contrast agent containing biomass
09/2003
09/30/2003US6627411 Method for evaluating matrix metalloprotease inhibitory activity
09/30/2003CA2133759C Evaluation and treatment of patients with progressive immunosuppression
09/30/2003CA2079748C Hydrophilic polyurethane membranes for electrochemical glucose sensors
09/28/2003CA2379661A1 Paracellular drug delivery system
09/25/2003WO2003079015A1 Optical imaging probes
09/25/2003WO2003077954A1 Method for determining effect of a clostridial toxin upon a muscle
09/25/2003WO2003077871A2 Method of diagnosis and treatment of breast lesions
09/25/2003WO2003077723A2 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003WO2003047494A3 Reverse micelle compositions and uses thereof
09/25/2003WO2002080757A3 Novel functional agents for magnetic resonance imaging
09/25/2003WO2002036161A3 Novel targeted compositions for diagnostic and therapeutic use
09/25/2003WO2002026982A3 Secreted human proteins
09/25/2003WO2002005634A3 Transgenic animal and methods
09/25/2003US20030182673 Calpain large subunit (n-CL4) cysteine protease gene disruptions, and compositions and methods related thereto
09/25/2003US20030181364 Genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.
09/25/2003US20030180817 Determining levels of a colon specific gene in the cells, or bodily fluids in a patient, comparing determined levels of CSG with levels of CSG in cells from normal human control, wherein a change in level of CSG indicates presence of cancer
09/25/2003US20030180800 Analyzing non-toxic stable labeled glucose isotope formation via mass spectrometry/nuclear magnetic resonance
09/25/2003US20030180491 Administering therapeutic dosage to mammals; immobilization
09/25/2003US20030180393 Cleaning digestion tracks
09/25/2003US20030180305 Pharmaceuticals for the imaging of angiogenic disorders
09/25/2003US20030180295 Angiocidin: a Cys-Ser-Val-Thr-Cys-Gly specific tumor cell adhesion receptor
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
09/25/2003US20030180224 Photosensitisers
09/25/2003US20030180223 Diagnostic imaging contrast agents with extended blood retention
09/25/2003US20030180222 Using paramagnetic chelate peptide compound
09/25/2003US20030180221 Water solubility, reduced toxicity; photodynamic therapy
09/25/2003US20030180220 Liposomes containing hydrophobic iodo compound
09/25/2003US20030178029 Method for determining effect of a clostridial toxin upon a muscle
09/25/2003CA2478762A1 Method for determining effect of a clostridial toxin upon a muscle
09/25/2003CA2478248A1 Methods and devices for detection and therapy of atheromatous plaque
09/25/2003CA2477828A1 Method of diagnosis and treatment of breast lesions
09/24/2003EP1346730A1 Pretargeting methods and novel pretargeting conjugates
09/24/2003EP1345968A2 Crystals of whole antibodies and fragments thereof and methods for making and using them
09/23/2003US6623722 Ultrasound echogenic contrast agents; higher yield; narrower size distribution; thinner shells; using such as ethanol in aqueous spray solution
09/23/2003CA2082936C Fluorescent porphyrin, and fluorescent phthalocyanine-polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes
09/18/2003WO2003076651A2 Cancer associated araf1 protein kinase and its uses
09/18/2003WO2003075977A2 Agglomerated particles for aerosol drug delivery
09/18/2003WO2003075961A2 Gold nanoparticles used for x-rays imaging
09/18/2003WO2003075960A1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy
09/18/2003WO2003075846A2 Uses of monoclonal antibody 8h9
09/18/2003WO2003075835A2 Compositions and methods for regulating thyroid hormone metabolism and cholesterol and lipid metabolism via the nuclear receptor car
09/18/2003WO2003075765A1 Biospecific contrast agents
09/18/2003WO2003075751A2 Overfeeding methods for determining therapeutic strategies and/or targets for obesity therapeutics
09/18/2003WO2003075747A2 Contrast agents for magnetic resonance imaging and methods related thereto
09/18/2003WO2003075742A2 Biomarker for efficacy of appetite suppressant drugs
09/18/2003WO2003059149A3 Methods for cancer imaging
09/18/2003WO2003057259A3 Indocyanine green (icg) compositions
09/18/2003US20030176639 Peptide-based compounds
09/18/2003US20030175921 Complexing antigen, antibodies; immunoassay
1 ... 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 ... 354